Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

BACKGROUND: Adalimumab (ADA) is approved for the management of lcerative colitis (UC) not responding to conventional therapy. Use of biologics in resource-constrained settings is very challenging. Currently, real-life data on the safety and efficacy of ADA biosimilar (Exemptia) in steroid-refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandra, Alok, Kanth, Ravi, Thareja, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883941/
https://www.ncbi.nlm.nih.gov/pubmed/31819364
http://dx.doi.org/10.2147/BTT.S214518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883941/
https://www.ncbi.nlm.nih.gov/pubmed/31819364
http://dx.doi.org/10.2147/BTT.S214518

Ejemplares similares